Ladenburg Thalmann Assumes UroGen Pharma at Buy, Announces Price Target of $31
URGNFebruary 19, 2025
Read more →D. Boral Capital Maintains Buy on UroGen Pharma, Maintains $25 Price Target
URGNFebruary 18, 2025
Read more →UroGen Announces Subgroup Analysis Results For ENVISION Study Of UGN-102 In LG-IR-NMIBC; Comparable CR Rates And DOR Observed Across Tumor Burden And Focality Levels
URGNFebruary 14, 2025
Read more →D. Boral Capital Maintains Buy on UroGen Pharma, Maintains $25 Price Target
URGNFebruary 12, 2025
Read more →UroGen Highlights Publication From Long-Term follow-Up Study With JELMYTO Showing Median Duration Of Response Of 47.8 Months
URGNFebruary 12, 2025
Read more →D. Boral Capital Maintains Buy on UroGen Pharma, Maintains $25 Price Target
URGNJanuary 15, 2025
Read more →UroGen Pharma Reports ENVISION Trial Results Published In The February Issue Of The Journal Of Urology Highlight UGN-102 Achievement Of 82.3% Duration Of Response at 12 Months Paving The Way For The Potential First FDA-Approved Treatment For LG-IR-NMIBC I
URGNJanuary 15, 2025
Read more →EF Hutton Maintains Buy on UroGen Pharma, Maintains $25 Price Target
URGNNovember 6, 2024
Read more →UroGen Pharma Expects Full-year 2024 JELMYTO Revenue To Be Below The Low End Of Previously Provided Guidance Range
URGNNovember 6, 2024
Read more →UroGen Pharma Q3 2024 GAAP EPS $(0.55) Beats $(0.83) Estimate, Sales $25.20M Beat $24.20M Estimate
URGNNovember 6, 2024
Read more →